Cargando…

Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs

A number of important drugs used to treat cancer—many of which serve as the backbone of modern chemotherapy regimens—have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribin...

Descripción completa

Detalles Bibliográficos
Autores principales: Balogh, Erin P., Bindman, Andrew B., Eckhardt, S. Gail, Halabi, Susan, Harvey, R. Donald, Jaiyesimi, Ishmael, Miksad, Rebecca, Moses, Harold L., Nass, Sharyl J., Schilsky, Richard L., Sun, Steven, Torrente, Josephine M., Warren, Katherine E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/
https://www.ncbi.nlm.nih.gov/pubmed/32162805
http://dx.doi.org/10.1634/theoncologist.2019-0698
_version_ 1783505293699710976
author Balogh, Erin P.
Bindman, Andrew B.
Eckhardt, S. Gail
Halabi, Susan
Harvey, R. Donald
Jaiyesimi, Ishmael
Miksad, Rebecca
Moses, Harold L.
Nass, Sharyl J.
Schilsky, Richard L.
Sun, Steven
Torrente, Josephine M.
Warren, Katherine E.
author_facet Balogh, Erin P.
Bindman, Andrew B.
Eckhardt, S. Gail
Halabi, Susan
Harvey, R. Donald
Jaiyesimi, Ishmael
Miksad, Rebecca
Moses, Harold L.
Nass, Sharyl J.
Schilsky, Richard L.
Sun, Steven
Torrente, Josephine M.
Warren, Katherine E.
author_sort Balogh, Erin P.
collection PubMed
description A number of important drugs used to treat cancer—many of which serve as the backbone of modern chemotherapy regimens—have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice.
format Online
Article
Text
id pubmed-7066705
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-70667052020-04-06 Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs Balogh, Erin P. Bindman, Andrew B. Eckhardt, S. Gail Halabi, Susan Harvey, R. Donald Jaiyesimi, Ishmael Miksad, Rebecca Moses, Harold L. Nass, Sharyl J. Schilsky, Richard L. Sun, Steven Torrente, Josephine M. Warren, Katherine E. Oncologist Commentaries A number of important drugs used to treat cancer—many of which serve as the backbone of modern chemotherapy regimens—have outdated prescribing information in their drug labeling. The Food and Drug Administration is undertaking a pilot project to develop a process and criteria for updating prescribing information for longstanding oncology drugs, based on the breadth of knowledge the cancer community has accumulated with the use of these drugs over time. This article highlights a number of considerations for labeling updates, including selecting priorities for updating; data sources and evidentiary criteria; as well as the risks, challenges, and opportunities for iterative review to ensure prescribing information for oncology drugs remains relevant to current clinical practice. John Wiley & Sons, Inc. 2019-12-08 2020-03 /pmc/articles/PMC7066705/ /pubmed/32162805 http://dx.doi.org/10.1634/theoncologist.2019-0698 Text en © 2019 The Authors. The Oncologist published by Wiley Periodicals, Inc. on behalf of AlphaMed Press. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Commentaries
Balogh, Erin P.
Bindman, Andrew B.
Eckhardt, S. Gail
Halabi, Susan
Harvey, R. Donald
Jaiyesimi, Ishmael
Miksad, Rebecca
Moses, Harold L.
Nass, Sharyl J.
Schilsky, Richard L.
Sun, Steven
Torrente, Josephine M.
Warren, Katherine E.
Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
title Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
title_full Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
title_fullStr Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
title_full_unstemmed Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
title_short Challenges and Opportunities to Updating Prescribing Information for Longstanding Oncology Drugs
title_sort challenges and opportunities to updating prescribing information for longstanding oncology drugs
topic Commentaries
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066705/
https://www.ncbi.nlm.nih.gov/pubmed/32162805
http://dx.doi.org/10.1634/theoncologist.2019-0698
work_keys_str_mv AT balogherinp challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT bindmanandrewb challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT eckhardtsgail challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT halabisusan challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT harveyrdonald challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT jaiyesimiishmael challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT miksadrebecca challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT mosesharoldl challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT nasssharylj challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT schilskyrichardl challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT sunsteven challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT torrentejosephinem challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs
AT warrenkatherinee challengesandopportunitiestoupdatingprescribinginformationforlongstandingoncologydrugs